Indaptus Therapeutics, Inc. (INDP)
Largest Insider Buys in Sector
INDP Stock Price History Chart
INDP Stock Performance
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August …
Insider Activity of Indaptus Therapeutics, Inc.
Over the last 12 months, insiders at Indaptus Therapeutics, Inc. have bought $0 and sold $0 worth of Indaptus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Indaptus Therapeutics, Inc. have bought $163,428 and sold $100,043 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,934 shares for transaction amount of $56,006 was made by Anderson Glen R. (10 percent owner) on 2023‑08‑14.
List of Insider Buy and Sell Transactions, Indaptus Therapeutics, Inc.
| 2023-08-14 | 10 percent owner | 23,934 0.2688% | $2.34 | $56,006 | -10.69% | |||
| 2023-08-11 | 10 percent owner | 35,064 0.3798% | $2.12 | $74,336 | -3.48% | |||
| 2023-08-10 | 10 percent owner | 44,354 0.482% | $1.94 | $86,047 | +0.45% | |||
| 2022-12-01 | Chief Medical Officer | 500 0.0063% | $1.87 | $935 | +8.94% | |||
| 2022-11-22 | Chief Medical Officer | 500 0.0061% | $1.83 | $915 | +4.95% | |||
| 2022-11-21 | CEO and Director | 9,600 0.122% | $1.90 | $18,240 | +5.25% | |||
| 2022-11-18 | CEO and Director | 400 0.0047% | $1.76 | $705 | +4.97% | |||
| 2022-09-08 | CEO and Director | 10,308 0.1329% | $2.80 | $28,862 | -29.85% | |||
| 2022-09-07 | Chief Business Officer | 150 0.0018% | $2.62 | $393 | -29.58% | |||
| 2022-09-06 | CEO and Director | 8,632 0.1092% | $2.57 | $22,184 | -25.00% | |||
| 2022-06-06 | CEO and Director | 19,727 0.2371% | $2.63 | $51,882 | -28.68% | |||
| 2022-03-02 | Chief Medical Officer | 50 0.0006% | $4.09 | $205 | -42.65% | |||
| 2022-02-01 | Sale | CSO and Director | 14,130 0.1722% | $5.00 | $70,692 | -49.70% | ||
| 2022-01-31 | Sale | CSO and Director | 5,870 0.0712% | $5.00 | $29,351 | -49.90% | ||
| 2022-01-31 | Chief Medical Officer | 100 0.0011% | $4.65 | $465 | -49.90% | |||
| 2021-11-18 | CEO and Director | 11,187 0.2847% | $5.82 | $65,108 | -44.81% | |||
| 2021-09-14 | CEO and Director | 12,000 0.2842% | $7.00 | $84,000 | -43.28% |
Insider Historical Profitability
| Anderson Glen R. | 10 percent owner | 1190400 11.6741% | $1.05 | 3 | 0 | |
| Meckler Jeffrey A | CEO and Director | 75374 0.7392% | $1.05 | 7 | 0 | <0.0001% |
| Litchev Boyan Vesselinov | Chief Medical Officer | 1150 0.0113% | $1.05 | 4 | 0 | <0.0001% |
| Linscott Walt Addison | Chief Business Officer | 150 0.0015% | $1.05 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $574,034.00 | 3 | 256,265 | 0% | +$0 | <0.0001 | |
| Investment House Llc | $229,459.00 | 1.2 | 102,437 | 0% | +$0 | 0.01 | |
| Geode Capital Management | $122,699.00 | 0.64 | 54,767 | 0% | +$0 | <0.0001 | |
| Strategy Asset Managers, LLC. | $101,553.00 | 0.53 | 45,336 | 0% | +$0 | 0.02 | |
| Renaissance Technologies | $58,000.00 | 0.31 | 26,100 | -11.22% | -$7,333.33 | <0.0001 |